Abstract PS1-11-02: The ADELA study: a double-blind, placebo-controlled, randomized phase 3 trial of elacestrant + everolimus versus elacestrant + placebo in ER+/HER2- advanced breast cancer (ABC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: A. Llombart-Cussac, J. M. Pérez-García, E. Lopez-Miranda, C. Saavedra, V. Carañana, I. Blancas, C. Hinojo, A. Cortes-Salgado, E. Galve-Calvo, R. R. Zhang, M. Sampayo-Cordero, D. Alcalá-López, J. Carvalho-Santos, O. Boix, A. Garrido, C. H. Barrios, G. Curigliano, R. Bartsch, A. Hardy-Bessard, T. Wasserman, J. Cortés
Institutions: Universidad Cardenal Herrera CEU, MedSIR (Spain), Hospital Arnau de Vilanova, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Granada, Instituto de Investigación Biosanitaria de Granada, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Hospital de Basurto, Latin American Cooperative Oncology Group (LACOG), University of Milan, European Institute of Oncology, Medical University of Vienna, UniCancer Group, Hospital Universitario de Torrejón, Universidad Europea de Madrid
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129729513